MedTrace Logo

Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy

NCT00694863 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-01-07

No results posted yet for this study

Summary

The purpose of this study is to determine whether treatment with long-acting synthetic adrenocorticotropic hormone is in the treatment of patients with idiopathic membranous nephropathy and high for renal failure.

Conditions

  • Idiopathic Membranous Nephropathy

Interventions

DRUG

tetracosactide hexacetaat

Intramuscular injections with tetracosactide hexacetaat (Synacthen Depot) 1ml a 1mg/ml. Treatment for 9 months with an increasing dosage from once per 2 weeks to twice a week.

Sponsors & Collaborators

  • Dutch Kidney Foundation

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Jack FM Wetzels, M.D.Ph.D. · Department of Nephrology, Radboud University

  • Julia M Hofstra, M.D. · Department of Nephrology, Radboud University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2010-12-31
Completion
2012-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00694863 on ClinicalTrials.gov